|
|
Article: CIMA LABS Announces Record Results for First Quarter of 2003; Revenues Nearly Double, Operating Income Rises More Than 150% Year-Over-Year.
- Article from:
- Business Wire
- Article date:
- May 1, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health/Medical Writers
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--May 1, 2003
CIMA LABS INC. (NASDAQ NMS: CIMA) today reported record operating results for the first quarter of 2003 ended March 31. Revenues nearly doubled and operating income was up more than 150% from the first quarter of 2002, driven by strong sales of Alavert(TM) and Remeron(R) SolTabs(TM), fast-dissolve medications that CIMA manufactures for its partners Wyeth and Organon.
-- Revenues totaled $16.7 million, an increase of 99% from the
year-earlier period and nearly 8% sequentially from $15.5
million in the fourth quarter of 2002.
-- ...